Sanjay Kaul, MD
Internal Medicine · Brownsville, KYNPI 1992777866
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,836 of the $69,010 with a category attached, or 70.8%. Boehringer Ingelheim India Pvt. Ltd. accounts for 66.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $50,764 and has fallen 99.3% since, to $360 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $831.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim India Pvt. Ltd.$46K
- Intercept Pharmaceuticals, Inc.$16K
- Boehringer Ingelheim Korea LTD.$4K
- Johnson & Johnson$824
- AstraZeneca$480
- Axsome Therapeutics, Inc.$403
- plus $1K from 12 others
What the payments were for
- Consulting fees$16,00023%
- Speaking & faculty fees$48,83671%
- Travel & lodging$1,0041%
- Food & beverage$3,1575%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim India Pvt. Ltd. | 2 | $45,876 |
| Intercept Pharmaceuticals, Inc. | 2 | $16,000 |
| Boehringer Ingelheim Korea LTD. | 2 | $3,964 |
| Johnson & Johnson | 18 | $824 |
| AstraZeneca | 8 | $480 |
| Axsome Therapeutics, Inc. | 4 | $403 |
| Lilly USA, LLC | 10 | $326 |
| Novo Nordisk | 16 | $260 |
| GSK | 3 | $203 |
| Bayer | 2 | $138 |
| Amgen(2 entities) | 3 | $138 |
| Radius Health, Inc. | 3 | $126 |
| Amarin Pharma, Inc. | 2 | $93 |
| AbbVie(2 entities) | 4 | $81 |
| Halozyme Inc | 1 | $50 |
| Novartis | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,010 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 277 | $197,933 |
| EliquisApixaban | 225 | $124,038 |
| OzempicSemaglutide | 85 | $98,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $88,563 |
| LinzessLinaclotide | 97 | $54,818 |
| FarxigaDapagliflozin Propanediol | 79 | $40,307 |
| VascepaIcosapent Ethyl | 91 | $35,053 |
| RybelsusSemaglutide | 29 | $34,796 |
| Wellbutrin XlBupropion Hcl | 12 | $30,843 |
| XareltoRivaroxaban | 29 | $23,909 |
| JanuviaSitagliptin Phosphate | 44 | $21,699 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $19,547 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $17,652 |
| TrulicityDulaglutide | 11 | $15,936 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $15,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $260 | $133,734114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $203 | $114,348189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $480 | $75,402149 claims |
| AbbVieLinzess | $81 | $54,81897 claims |
| Johnson & JohnsonXarelto | $824 | $23,90929 claims |
| Lilly USA, LLCTrulicity | $326 | $15,93611 claims |
| NovartisEntresto | $23 | $8,94113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Brownsville
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
- Kelley McIntyreLouisville$48K
- Justin CaseFlorence$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.